Path Analysis Identifies Receptor Activator of Nuclear Factor-κB Ligand, Osteoprotegerin, and Sclerostin as Potential Mediators of the Tophus-bone Erosion Relationship in Gout

REFERENCES

1. 1.↵
   1. Dalbeth N,
   2. Clark B,
   3. Gregory K,
   4. Gamble G,
   5. Sheehan T,
   6. Doyle A,
   7. et al.

   Mechanisms of bone erosion in gout: a quantitative analysis using plain radiography and computed tomography. Ann Rheum Dis 2009;68:1290–5.

   OpenUrlAbstract/FREE Full Text
2. 2.↵
   1. Chhana A,
   2. Callon KE,
   3. Pool B,
   4. Naot D,
   5. Watson M,
   6. Gamble GD,
   7. et al.

   Monosodium urate monohydrate crystals inhibit osteoblast viability and function: implications for development of bone erosion in gout. Ann Rheum Dis 2011;70:1684–91.

   OpenUrlAbstract/FREE Full Text
3. 3.↵
   1. Dalbeth N,
   2. Smith T,
   3. Nicolson B,
   4. Clark B,
   5. Callon K,
   6. Naot D,
   7. et al.

   Enhanced osteoclastogenesis in patients with tophaceous gout: urate crystals promote osteoclast development through interactions with stromal cells. Arthritis Rheum 2008;58:1854–65.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Sims NA,
   2. Martin TJ

   . Coupling the activities of bone formation and resorption: a multitude of signals within the basic multicellular unit. Bonekey Rep 2014;3:481.

   OpenUrlPubMed
5. 5.↵
   1. Baron R,
   2. Kneissel M

   . WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med 2013;19:179–92.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Fairchild AJ,
   2. MacKinnon DP

   . A general model for testing mediation and moderation effects. Prev Sci 2009;10:87–99.

   OpenUrlCrossRefPubMed
7. 7.↵
   1. Dalbeth N,
   2. Aati O,
   3. Gamble GD,
   4. Horne A,
   5. House ME,
   6. Roger M,
   7. et al.

   Zoledronate for prevention of bone erosion in tophaceous gout: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 2014;73:1044–51.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   1. Wallace SL,
   2. Robinson H,
   3. Masi AT,
   4. Decker JL,
   5. McCarty DJ,
   6. Yu TF

   . Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977;20:895–900.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Dalbeth N,
   2. Doyle A,
   3. Boyer L,
   4. Rome K,
   5. Survepalli D,
   6. Sanders A,
   7. et al.

   Development of a computed tomography method of scoring bone erosion in patients with gout: validation and clinical implications. Rheumatology 2011;50:410–6.

   OpenUrlAbstract/FREE Full Text
10. 10.↵
    1. Dalbeth N,
    2. Milligan A,
    3. Doyle AJ,
    4. Clark B,
    5. McQueen FM

    . Characterization of new bone formation in gout: a quantitative site-by-site analysis using plain radiography and computed tomography. Arthritis Res Ther 2012;14:R165.

    OpenUrlCrossRefPubMed
11. 11.↵
    1. Winnard D,
    2. Wright C,
    3. Taylor WJ,
    4. Jackson G,
    5. Te Karu L,
    6. Gow PJ,
    7. et al.

    National prevalence of gout derived from administrative health data in Aotearoa New Zealand. Rheumatology 2012;51:901–9.

    OpenUrlAbstract/FREE Full Text
12. 12.↵
    1. Dalbeth N,
    2. House ME,
    3. Horne A,
    4. Taylor WJ

    . Reduced creatinine clearance is associated with early development of subcutaneous tophi in people with gout. BMC Musculoskelet Disord 2013;14:363.

    OpenUrlCrossRefPubMed
13. 13.↵
    1. Hein GE,
    2. Meister M,
    3. Oelzner P,
    4. Franke S

    . sRANKL and OPG in serum and synovial fluid of patients with rheumatoid arthritis in comparison to non-destructive chronic arthritis. Rheumatol Int 2008;28:765–9.

    OpenUrlCrossRefPubMed
14. 14.↵
    1. van Tuyl LH,
    2. Voskuyl AE,
    3. Boers M,
    4. Geusens P,
    5. Landewe RB,
    6. Dijkmans BA,
    7. et al.

    Baseline RANKL:OPG ratio and markers of bone and cartilage degradation predict annual radiological progression over 11 years in rheumatoid arthritis. Ann Rheum Dis 2010;69:1623–8.

    OpenUrlAbstract/FREE Full Text
15. 15.↵
    1. Geusens PP,
    2. Landewe RB,
    3. Garnero P,
    4. Chen D,
    5. Dunstan CR,
    6. Lems WF,
    7. et al.

    The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction. Arthritis Rheum 2006;54:1772–7.

    OpenUrlCrossRefPubMed
16. 16.↵
    1. Lee SJ,
    2. Nam KI,
    3. Jin HM,
    4. Cho YN,
    5. Lee SE,
    6. Kim TJ,
    7. et al.

    Bone destruction by receptor activator of nuclear factor kappaB ligand-expressing T cells in chronic gouty arthritis. Arthritis Res Ther 2011;13:R164.

    OpenUrlCrossRefPubMed
17. 17.↵
    1. Winkler DG,
    2. Sutherland MK,
    3. Geoghegan JC,
    4. Yu C,
    5. Hayes T,
    6. Skonier JE,
    7. et al.

    Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J 2003;22:6267–76.

    OpenUrlAbstract/FREE Full Text
18. 18.↵
    1. Nakashima T,
    2. Hayashi M,
    3. Fukunaga T,
    4. Kurata K,
    5. Oh-hora M,
    6. Feng JQ,
    7. et al.

    Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med 2011;17:1231–4.

    OpenUrlCrossRefPubMed
19. 19.↵
    1. Kramer I,
    2. Halleux C,
    3. Keller H,
    4. Pegurri M,
    5. Gooi JH,
    6. Weber PB,
    7. et al.

    Osteocyte Wnt/beta-catenin signaling is required for normal bone homeostasis. Mol Cell Biol 2010;30:3071–85.

    OpenUrlAbstract/FREE Full Text
20. 20.↵
    1. Dalbeth N,
    2. Doyle AJ,
    3. McQueen FM,
    4. Sundy J,
    5. Baraf HS

    . Exploratory study of radiographic change in patients with tophaceous gout treated with intensive urate-lowering therapy. Arthritis Care Res 2014;66:82–5.

    OpenUrlCrossRef